A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 961 participants.
Also called NCT03989232
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 961 participants
- Sponsor
- Registry
-
NCT03989232 -
2018-004529-96
-
- Other papers using this trial's data
- Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Canada, Czechia, Greece, Hungary, Japan, Poland, Puerto Rico, Slovakia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT03989232. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-19 (actual); primary completion 2020-09-18 (actual). Results posted on 2021-10-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
- Acronym
- SUSTAIN FORTE
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo (semaglutide)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03989232- Content hash
8107fa941823e13aac41a22c67c1f4395b6aa42cc186a9bbdb80d17dd8e393e5